ISSN 0028-4793
15 papers in the library · 2,603 citations · publishing 1958-2023
New England Journal of Medicine November 4, 2023 Mason Marks, I. Glenn Cohen 11 citations
Mounting clinical evidence could lead to the approval of new psychedelic medicines. The FDA’s draft guidance on psychedelics research includes several recommendations that may be contentious.
New England Journal of Medicine October 4, 2023 Andreas Reif, Istvan Bitter, Jozefien Buyze et al. 197 citations
BACKGROUND: In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments during the current depressive episode, the percentage of patients with remission is low and the percentage with relapse is high. The efficacy and safety of esketamine nasal spray as compared with extended-release quetiapine augmentation therapy, both in combination with...
New England Journal of Medicine May 24, 2023 A. Anand, S. Mathew, Gerard Sanacora et al. 263 citations
BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain. METHODS We conducted an open-label, randomized, noninferiority trial involving patients referred to ECT clinics for treatment-resistant major depression. Patients with...
New England Journal of Medicine November 2, 2022 Bertha K. Madras 36 citations
Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic drain on nations.1 At least 30 drugs are Food and Drug Administration (FDA)–approved to treat depression,2 yet a systematic review and meta-analysis of 22 antidepressants concluded that although they were more effective than placebo in adults with...
New England Journal of Medicine April 14, 2021 Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al. 1,372 citations
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...
New England Journal of Medicine April 14, 2021 Jeffrey A. Lieberman 18 citations
In The Doors of Perception, Aldous Huxley described his trial of mescaline as "the most extraordinary and significant experience available to human beings this side of the Beatific Vision." His exegesis was preceded by the synthesis of the hallucinogen lysergic acid diethylamide (LSD) by Sandoz chemist Albert Hoffman in 1938 and was followed by Hoffman's extraction of psilocybin from Psilocybe...
New England Journal of Medicine May 22, 2019 Jean Kim, Tiffany R. Farchione, Andrew Potter et al.
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset...
New England Journal of Medicine January 14, 2009 Dianne W. M. Hoelen, Wilko Spiering, Gerlof D. Valk 48 citations
A 31-year-old woman was admitted to the emergency department because of a seizure-like attack after a single 3.5-g dose of ibogaine. ECG showed a severe prolonged-QT interval of 548 msec and ventri...
New England Journal of Medicine October 31, 2007 Dirk de Ridder, Koen van Laere, Patrick Dupont et al. 225 citations
An out-of-body experience was repeatedly elicited during stimulation of the posterior part of the superior temporal gyrus on the right side in a patient in whom electrodes had been implanted to suppress tinnitus. Positron-emission tomographic scanning showed brain activation at the temporoparietal junction--more specifically, at the angular-supramarginal gyrus junction and the superior temporal...
New England Journal of Medicine May 6, 1999 Scott Mintzer, Susan L. Hickenbottom, Sid Gilman 56 citations
To the Editor: Recreational use of 3,4-methylenedioxymethamphetamine (MDMA, or “ecstasy”), a hallucinogen, has increased both in Europe and the United States.1 This substance is manufactured in illicit laboratories from a variety of organic ketone precursors. MDMA, which is structurally related both to the stimulant amphetamine and to the hallucinogen mescaline, promotes the release of both...
New England Journal of Medicine April 23, 1970 Margaret J. Corey, J. C. Andrews, M.Josephine McLeod et al. 25 citations
In a prospective study of 10 patients given d-lysergic acid diethylamide 25, there was no difference in frequency of chromosome breakage between samples obtained immediately before and 24 hours after treatment. In 11 patients, treated over periods ranging from 24 hours to eight years before sampling, the frequency of chromosomal breaks did not differ from that found in untreated controls. In an...
New England Journal of Medicine February 22, 1968 Donald B. Louria 69 citations
NO drug used by man has stimulated greater public-debate than lysergic acid diethylamide (LSD). This brief review of the current status of the drug will summarize its pharmacology, medical uses and dangers. No attempt will be made to analyze in detail its alleged benefits when taken indiscriminately or under uncontrolled circumstances; these include augmented aesthetic sensitivity, enhanced...
New England Journal of Medicine November 16, 1967 Maimon M. Cohen, Kurt Hirschhorn, William A. Frosch 150 citations
THE induction of chromosomal aberrations by exogenous agents, such as viruses, radiation and chemicals, is an area of active cytogenetic investigation.1 Recently, the psychotomimetic hallucinogen, lysergic acid diethylamide (LSD-25), has been added to the list of chemicals capable of causing abnormalities in the chromosomes of human leukocytes.2 , 3 Such preliminary studies report the in vitro...
New England Journal of Medicine December 2, 1965 William A. Frosch, Edwin Robbins, Marvin Stern 115 citations
MOST typically, medical research has proceeded from clinical observation to clinical investigation to laboratory experiment. Some of the striking exceptions to this pattern have been studies of a variety of pharmacologic agents that are capable of producing changes in psychic state. These drugs, first isolated or synthesized in the laboratory, occasionally create a new clinical syndrome or a...
New England Journal of Medicine January 2, 1958 George B. Koelle 18 citations
DURING the last few years a great revival of interest has occurred in the search for a biochemical basis for schizophrenia and the other types of psychosis. There are several reasons for this. Modern laboratory technics permit the detection and accurate quantitation of substances in the blood and tissues for which satisfactory procedures were not available formerly. The discovery of a partially...